U Wahnschaffe, A Bitsch, J Kielhorn, I Mangelsdorf
Fraunhofer Institute of Toxicology and Experimental Medicine ITEM, Department of Chemical Risk Assessment, Nikolai-Fuchs-Str. 1, 30625 Hannover, Germany
| Date of Submission | 26-May-2004 |
| Date of Acceptance | 17-Jan-2005 |
| Date of Web Publication | 17-Jan-2005 |
Correspondence Address:
J Kielhorn
Fraunhofer Institute of Toxicology and Experimental Medicine ITEM, Department of Chemical Risk Assessment, Nikolai-Fuchs-Str. 1, 30625 Hannover
Germany.
Source of Support: None, Conflict of Interest: None
DOI: 10.1186/1477-3163-4-3
Abstract
As part of a larger literature study on transgenic animals in mutagenicity testing, test results from the transgenic mutagenicity assays ( lacI model; commercially available as the Big Blue® mouse, and the lacZ model; commercially available as the Muta™Mouse), were compared with the results on the same substances in the more traditional mouse bone marrow micronucleus test. 39 substances were found which had been tested in the micronucleus assay and in the above transgenic mouse systems. Although, the transgenic animal mutation assay is not directly comparable with the micronucleus test, because different genetic endpoints are examined: chromosome aberration versus gene mutation, the results for the majority of substances were in agreement. Both test systems, the transgenic mouse assay and the mouse bone marrow micronucleus test, have advantages and they complement each other. However, the transgenic animal assay has some distinct advantages over the micronucleus test: it is not restricted to one target organ and detects systemic as well as local mutagenic effects.
| How to cite this article: Wahnschaffe U, Bitsch A, Kielhorn J, Mangelsdorf I. Mutagenicity testing with transgenic mice. Part I: Comparison with the mouse bone marrow micronucleus test. J Carcinog 2005;4:3 |
| How to cite this URL: Wahnschaffe U, Bitsch A, Kielhorn J, Mangelsdorf I. Mutagenicity testing with transgenic mice. Part I: Comparison with the mouse bone marrow micronucleus test. J Carcinog [serial online] 2005 [cited 2021 Oct 15];4:3. Available from: https://carcinogenesis.com/text.asp?2005/4/1/3/42208 |
Background
This and the following presentation are part of a project for the International Programme on Chemical Safety (IPCS) evaluating the possible use of transgenic animal mutagenicity assays in chemical toxicity testing and mechanistic research. It was decided to compare the results obtained from those transgenic mutagenicity test systems where considerable data was available, with other in vivo genotoxicity tests: in the first article (Part 1) with the mouse bone marrow micronucleus test and in the second (Part II) with the mouse spot test.
The mouse bone marrow micronucleus test is one of several available in vivo mammalian test system for the detection of chromosomal aberrations [1-5]. A documentation of the test procedure and evaluation of results is given in the OECD guideline 474 [6]. This test is routinely used with a widespread acceptance in industry and authorities.
Mutagenicity assays using transgenic animals have been developed in particular the lacI model [7] (commercially available as the Big Blue® mouse), and the lacZ model [8] (commercially available as the Muta™Mouse). In this article, available data on the results of mouse bone marrow micronucleus test were compared with results from these two transgenic mouse assays for 39 substances. The advantages and disadvantages of the test systems are discussed. Recently, further transgenic rodent mutation assays have been developed, however, the data base is not sufficient for comparison with other test systems.
The mouse bone marrow micronucleus test: principles and procedure
Micronuclei are chromatin-containing bodies in the cytoplasm arising from acentric chromosome fragments or from whole chromosomes that were not incorporated in the daughter nuclei during the last stages of mitosis. Chromosome fragments are associated with the clastogenic (chromosome breakage) activity of the test substance whereas the presence of a whole chromosome is indicative of an adverse effect of the test substance on the mitotic spindle apparatus (aneugenic effects). The difference in size of the micronucleus is therefore an indicator for clastogenicity (small micronucleus) or aneugenicity (large micronucleus). However, the size of the micronucleus is an inaccurate measure. Micronuclei can be distinguished by further criteria, for example by identification of the presence of a kinetochore or centromeric DNA, indicating aneugenic activity. Overall, an increase in micronuclei is an indirect measure of induced structural or numerical chromosome aberrations [1,2].
In the micronucleus test according to the OECD guideline 474, erythroblasts in the bone marrow of mice (or rats) are used as target cells. When a bone marrow erythroblast develops into a polychromatic erythrocyte, the main nucleus is extruded. Any micronucleus that has been formed may remain in the otherwise anucleated cytoplasm and can easily been detected. An increase in the frequency of micronucleated polychromatic erythrocytes in treated animals is an indication of induced chromosome damage [6].
In the last three decades, toxicologists have often used the mouse bone marrow micronucleus test because 1) it is part of the regulatory toxicology in the admission procedure for chemicals and drugs and 2) it has advantages in speed, simplicity, and cost effectiveness in comparison to other in vivo systems for testing chromosomal aberrations (e.g. the cytogenetic test).
Transgenic mouse models
Transgenic mutation test systems contain a foreign gene construct having two essential parts: the transgene containing the target gene that serves as target for mutations, and a shuttle vector for recovering the target gene DNA from the tissue of the transgenic animal. The transgene is constructed using recombinant DNA technologies.
LacI transgenic mouse model (Big Blue® mouse)
The proprietary mouse of the Big Blue® mutagenesis assay system contains about 30-40 copies of a lambda LIZα shuttle phage vector integrated into its genome at a single locus on chromosome 4. The target site for mutagenesis is the lacI gene [7].
The test compound is administered to the mouse either as a single or repeated dose. After the post treatment period for manifestation of the DNA lesions, the tissue of interest is isolated and the DNA extracted. A proprietary lambda DNA packaging extract automatically excises the lambda vector target and packages it into a lambda phage head and the phage is transfected to bacteria. These bacteria are plated on agar indicator plates containing the chromogenic substance (X-gal). The phage transfected bacteria with mutations in the lacI gene form blue plaques, whereas bacteria with a nonmutated lacI form colourless plaques. The ratio between blue and white plaques is a measure of the mutagenicity. [7,9].
LacZ transgenic mouse model (Muta™Mouse)
The lambda-gt10- lacZ shuttle vector for the lacZ mouse model contains the entire lacZ target gene [8]. The commercially available lacZ mouse model contains about 80 copies of the shuttle vector at chromosome 3.
As above, the test compound is administered to the mouse, the genomic DNA is isolated from the tissue of interest, and the lambda genomes are excised by and packed with a bacteriophage packaging extract. The resulting phage particles are then plated on a lacZ – E. coli strain (for transfection) in the presence of the chromogenic substance (X-gal) as indicator. The plaques containing an intact lacZ are β-galactosidase active and are blue, whereas plaques containing mutated lacZ will be white/colourless. In this original model the ratio between colourless and blue plaques is a measure of the mutagenicity. Due to optical difficulties in the evaluation of plaques, this system has been improved using a selection assay in lieu of colour screening whereby only mutant particles form plaques [10]. The number of plaques under non-selective conditions is a measure for the total number of phage-transfected bacteria (intact or mutant lacZ gene). The ratio between the number of plaques produced under selective conditions versus the number of plaques under non-selective conditions is a measure of the mutagenicity [9,10].
Methods
Data presented in this documentation are the results of an extensive literature research. Concerning data on transgenic mouse assays only primary literature was used. Data on the mouse bone marrow micronucleus assay were extracted from reliable reviews on this item or from primary literature. For all other data informations from secondary literature or data compilation bases were used.
Results and Discussion
Comparison of data from the mouse bone marrow micronucleus test and transgenic mouse test
The authors are aware that a comparison of the transgenic mouse assays with the mouse bone marrow micronucleus test is limited by the fact that different genotoxic endpoints are studied in these two systems. In transgenic mouse assays, point mutations and small insertions and deletions are detected whereas in the mouse bone marrow assay, chromosome breakage leading to light microscopically visible micronuclei resulting from chromosome fragment or micronuclei originated from whole chromosomes are investigated. However, both point mutations and micronuclei may be induced by a single agent, so some overlap of results is to be expected.
From the literature, 39 substances were identified with data on the mouse bone marrow micronucleus test and the Muta™mouse assay (n = 29) or the Big Blue® mouse assay (n = 21) or both transgenic mutation assays (n = 11); see for references. Agreement between the Muta™mouse and the micronucleus test was seen with 18 out of 29 substances, no agreement with 8 substances and in 3 cases the comparison is inconclusive because of questionable results in the micronucleus assay. With the Big Blue® mouse assay, the results obtained with 14 out of 21 substances agreed with results in the mouse micronucleus test, but 6 showed no agreement and another was inconclusive.
Most substances included in this comparison are also carcinogenic in long-term assays on mice. No data on carcinogenicity in mice are available for 4-acetylaminofluorene and negative results were obtained with bromomethane and 2,6-diaminotoluene.
Carcinogenic substances with positive results in the bone marrow micronucleus and transgenic gene mutation assays
Studies with Muta™mouse
The following 17 substances were gene mutagenic in at least one of the examined organs in the Muta™mouse assay, induced micronuclei in mouse bone marrow and showed positive results in carcinogenicity studies on mice: 2-acetylaminofluorene, 4-aminobiphenyl, benzo(a)pyrene, 1,3-butadiene, chlorambucil, cyclophosphamide, 7,12-dimethylbenz(a)anthracene, ethylmethanesulfonate, N-ethyl-N-nitrosourea, methylmethane-sulfonate, N-methyl-N’-nitro-N-nitrosoguanidine, N-methyl-N-nitrosourea, 4-nitroquinoline-1-oxide, N-nitrosodimethylamine, procarbazine, quinoline, and urethane. Further studies on chromosome aberration in vitro and in vivo (see ) supported the results in the micronucleus test, except data on 4-aminobiphenyl (negative micronucleus test in rats) and quinoline (see below).
Of the substances tested for mutagenic activity in bone marrow in Muta™mice, 14 gave positive results, only 1,3-butadiene, methylmethanesulfonate, and quinoline were negative, indicating that other organs are more sensitive. 1,3-Butadiene is clearly clastogenic in other studies on chromosome aberration in mice and induced gene mutation in the bone marrow of Big Blue® mice (see ). Quinoline, however, gave inconclusive results in other in vivo studies on clastogenic effects in bone marrow of rats and mice.
Studies with Big Blue® mouse
12 substances showed gene mutagenic effects in at least one of the examined organs in the Big Blue® mouse assay, chromosome mutagenic effects in the mouse bone marrow micronucleus assay and induced carcinogenic effects in long-term assays on mice,: 2-acetylaminofluorene, aflatoxin B1, benzene, benzo(a)pyrene, 1,3-butadiene, cyclophosphamide, 7,12-dimethylbenz(a)anthracene, ethylene oxide, N-ethyl-N-nitrosourea, N-methyl-N-nitrosourea, N-nitrosodimethylamine, urethane. In the Big Blue® mouse assay the target organ bone marrow revealed also increased mutation frequencies induced by benzene, 1,3-butadiene, and 7,12-dimethylbenz(a)anthracene. However, negative results in bone marrow were obtained with cyclophosphamide, ethylene oxide, and N-nitrosodimethylamine, indicating that other target organs are more sensitive in the Big Blue® mouse assay. All of these 12 substances induced also chromosome aberrations in majority of further in vitro and in vivo studies.
Substances with carcinogenic effects in mice but no agreement between the transgenic mouse assay and the mouse bone marrow assay
Acrylamide
The inconclusive result in the bone marrow micronucleus test [4] is contradictory to the Muta™mouse assay [21-23] which shows mutagenic activity in the target organ bone marrow but also contradictory to other in vivo tests on the endpoint chromosome aberration including a cytogenetic test on mice [4, 19, 21]. Micronuclei were detected in spleen and testis of mice [4]. Overall, using other experimental design the mouse bone marrow micronucleus assay might give clearly positive results.
2-Amino-3-methylimidazo(4,5-f)quinoline (IQ)
IQ is mutagenic in the liver of the Muta™mouse [34] but negative results were obtained in the mouse bone marrow micronucleus test [2,35]. This negative result is supported by a negative cytogenetic assay on mice. Inconclusive results were obtained in in vitro studies on chromosome aberrations but IQ induced micronuclei in rats (see ). This discrepancy might be due to the possibility that a) the liver but not the bone marrow of mice is target organ (the liver but not the blood is target organ in carcinogenicity [33]) or b) IQ is less clastogenic than gene mutagenic in mice.
ortho-Anisidine
The target organ of carcinogenesis in mice (and humans) is the bladder [36]. In the Big Blue® assay on mice mutagenic activity was detected in the bladder but not in the liver [37]. As expected, the mouse bone marrow micronucleus test [4,36] gave negative results (also in rats; see ), because the bone marrow is presumably not a target organ of mutagenicity.
Asbestos crocidolite
Local carcinogenic effects were observed in carcinogenicity studies, the lung is the target organ after inhalation [38-40]. Mutagenic activity was detected in the lung of Big Blue® mice after inhalation [41]. As expected, clearly no systemic effects in the bone marrow could be observed in the mouse micronucleus test [4].
2,4-Diaminotoluene
The main target organ in carcinogenicity is the liver (also in rats) [81]. Positive results were reported in two Big Blue® mouse assays examining the liver [82-84]. The mouse micronucleus test gave negative results [4], however, systemic effects in the bone marrow are not expected from carcinogenicity studies. Results of other studies on chromosome aberration in vivo are inconclusive (see ).
Hydrazine
This substance induced no mutagenic effects in lung, liver, or bone marrow of the Muta™mouse which were target organs in mouse carcinogenicity studies [119,120]. The mouse bone marrow micronucleus test gave positive results after repeated application [4,119]. However, single exposure was used in the Muta™mouse assay [120]. Studies on other in vivo genotoxicity endpoints have shown almost negative results after single exposure but genotoxic activity after repeated application, for example in the mouse bone marrow micronucleus assay [4]. Positive results might be expected in the Muta™mouse assay using another experimental design since other in vivo as well as in vitro test systems revealed gene mutagenic effects.
Methyl methanesulfonate
Only weak mutagenic effects in the liver but no effects in bone marrow were observed in the Muta™mouse [18,124] and negative results in the Big Blue® mouse [111-113,126]. In the mouse bone marrow micronucleus test this carcinogenic substance induced chromosome aberration [1,127]; other in vitro and in vivo assays clearly supported the clastogenic activity [121,122]. There is evidence that the chromosome mutagenic activity is detectable at much lower doses than the gene mutagenic activity. Tinwell et al. (1998) [18] have shown on Muta™mice a weak gene mutagenic effect in the liver but no effect in the bone marrow. The same dose induced in these animals a significant increase in bone marrow micronuclei indicating clear clastogenic activity. Overall, methyl methanesulfonate is more clastogenic than gene mutagenic.
Mitomycin C
A very similar situation is given with mitomycin C. No mutagenic activity was observed in the Muta™mouse assay in liver and bone marrow after single injection but the same dose induced chromosome aberrations in the bone marrow of the same mice [142]. The mouse bone marrow micronucleus test [1,47] and all in vivo and in vitro assays on the endpoint chromosome aberration revealed clearly positive results [139-141].
N-Nitrosodiethylamine
The main target organ in systemic carcinogenesis is the liver [146-148]. As expected, mutagenic effects were detected in the liver of the Muta™mouse, but none in the bone marrow [104, 106, 149, 150]. The same mice showed also no micronuclei at these dose levels [104]. Consequently, the mouse bone marrow micronucleus test gave negative results indicating that this is not a target organ of genotoxicity. However, there is also evidence that this substance shows more gene mutagenic activity than clastogenic activity because other in vivo studies gave no clear indication for chromosome aberration (see ).
N-Nitrosodi-N-propylamine
There is evidence that this substance shows more gene than chromosome mutagenic activity. Beside local carcinogenic effects in carcinogenicity studies on mice and rats systemic effects were located in the liver (mouse and rats) and in bone marrow (rat) [160-163]. Several target organs were detected in the Muta™mouse assay including liver and bone marrow [164]. But no chromosome mutagenic activity was recorded in the mouse bone marrow micronucleus test [4]. Further in vivo data on this endpoint are not available (see ).
Phenobarbital
Liver tumours were detected in carcinogenicity studies on mice and rats [165-167]. In the Muta™mouse assay no mutagenic activity was observed although the liver weight of the treated mice increased indicating systemic effects in this organ [149,168]. Two studies are available on the Big Blue® mouse, one gave negative [16] and the other weak positive results [169]. Taken together the results in transgenic mice are inconclusive which is in accord with the mouse bone marrow nucleus test (inconclusive results). Inconclusive ( in vitro ) or negative results were obtained in other studies on clastogenicity or other endpoints of genotoxicity (see ).
Overall, there is no clear indication of gene or chromosome mutagenic activity in transgenic mouse assays or other genotoxic tests systems. However, genotoxic mechanisms in carcinogenicity cannot be excluded.
β-Propiolactone
This is an alkylating substance with predominantly local carcinogenic effects [175,176]. In the Muta™mouse assay [131] local effects in the stomach were observed in gavage studies plus systemic effects in the liver, but no mutagenic activity was seen in bone marrow of the Muta™mouse [131]. As expected, no increased incidence in micronuclei was detected in the bone marrow of treated mice [1,4] although clastogenic effects were observed in in vitro studies, in insects and plants (see ) indicating chromosomal aberration after direct contact with this alkylating substance.
Trichloroethylene
This substance gave clearly positive results in different carcinogenicity studies on mice [186]. Although the target organs of carcinogenicity (including bone marrow) were investigated in the Muta™mouse assay, no mutagenic activity was noted [187]. The positive results in the mouse bone marrow micronucleus test are contradictory to other in vivo studies on clastogenicity. However, a further (simple) reason for the negative results in the Muta™mouse assay might be that the MTD was not reached [187]. Overall, further discussion on the mechanisms of carcinogenicity is necessary.
Tris(2,3-dibromopropyl)phosphate
This might be a further example for a substance where genotoxic effects are not related to the target organ bone marrow but induce systemic effects in others. The target organ in oral carcinogenicity studies on mice and rats was the kidney, in mice systemic carcinogenic effects were also seen in lung and liver [188-190]. In the Big Blue® mouse assay, mutagenic activity was detected in the kidney in gavage studies [46,191]. The mouse bone marrow micronucleus assay (i.p. injection)[4] as well as cytogenetic studies on rats and mice were negative [188-190].
Substance without data on carcinogenicity in mice and differing results in the micronucleus test and transgenic mouse assay
4-Acetylaminofluorene
This substance showed mutagenic activity in the Muta™mouse assay [18] but inconclusive results in the mouse bone marrow micronucleus test [2]. No data on carcinogenicity are available on 4-acetylaminofluorene. However, data on two in vitro mammalian test systems indicated gene mutagenic activity [17] supporting results in the transgenic assay.
Substances without carcinogenic effects in mice and differing results in the micronucleus test and transgenic mouse assay
Bromomethane
No increased tumour incidences were observed in mice as well as in re-evaluated studies on rats [58,59]. Negative results were obtained also in the examined organs including liver and bone marrow in the Muta™mouse assay. However, DNA methylation in the liver was observed in the same assay even at lower dose levels [60] indicating differences in the sensitivity of these two genotoxic endpoints. The mouse micronucleus test revealed chromosome mutagenic activity [61] although results of other in vivo tests are equivocal (see ).
2,6-Diaminotoluene
No carcinogenic effects were seen in a valid long-term study on mice and rats [85]. In the Big Blue® mouse no mutagenic activity was induced [82,84]. However, only the liver was examined and the assays had some limitations (one dose tested, MTD possibly not reached). The mouse micronucleus test revealed chromosome aberrations [3,47] as well as the available in vitro studies but no clastogenic activity was detected in a cytogenetic study on rodents (see ).
Substances with carcinogenic effects in mice but nongenotoxic mechanisms are presumed
Chloroform (German MAK Classification 4 = substances with carcinogen effects where the genotoxic effects are absent or only play an insignificant role)
Liver tumours were induced in B6C3F1 mice [72], however no mutagenic effects were detected in the liver of Big Blue® mice of the same strain in a valid assay [74]. Accordingly, no increased incidence in micronuclei were observed in the bone marrow of mice [1,47] and no clastogenicity in in vitro studies (see ). In contrast, rats showed clastogenic activity in the kidney, but only at toxic dose levels [73].
Di-(2-ethylhexyl)phthalate (German MAK Classification 4)
This substance induced liver tumours in mice and rats [86]. No increased mutation frequency was seen in the liver of the Big Blue® mouse [16] (limited validity, MTD presumably not reached) and no chromosome aberration in the mouse micronucleus test [4]. The majority of in vitro and in vivo tests revealed also negative results with di-(2-ethylhexyl)phthalate (see ).
Tetrachloromethane (German MAK Classification 4)
An increased incidence of liver tumours were induced in mice and in rats [185]. However, no mutagenic activity in the liver was reported in a Muta™mouse assay although the organ weight increased in the same mice indicating some hepatocellular regeneration [168]. No chromosome aberration was induced in the mouse bone marrow micronucleus test [4]. Also other studies on this endpoint and the majority studies on other endpoint of genotoxicity revealed negative results (see ).
Discussion on the comparison of both assays
Most carcinogens in are positive in transgenic mouse assays and in the mouse bone marrow micronucleus test although different endpoints are studied. This indicates coincidence in both test systems and/or effects of the test substance on different genotoxic endpoints.
However, there are several substances (see above for example ortho-anisidine) whose mutagenic (and carcinogenic) potential could not be demonstrated with the mouse bone marrow micronucleus test but with the transgenic mouse assay. This might be due to the fact that the micronucleus test is restricted to the bone marrow as target organ. In contrast, all organs can be examined in transgenic mouse assay for mutagenic activity without any restrictions.
A special subgroup of substances should also be mentioned: substances with predominantly local mutagenic/carcinogenic effects and less systemic direction of effects. For these substances the mouse bone marrow micronucleus test is an unsuitable test system.
Beside the restrictions on the target organ there is also given the possibility that a substance induces predominantly gene mutations and not or less chromosome aberrations at the same dose level. The example N -nitrosodi- N -propylamine has shown positive results in different target organs including the bone marrow using the transgenic mouse assay but negative results were shown in the mouse micronucleus test.
On the other hand there are also substances for which the transgenic mouse assay is an unsuitable test system. The examples methylmethanesulfonate and mitomycin C have shown that chromosome aberration and not gene mutation is the predominant endpoint at the corresponding dose level in vivo . These genotoxic effects are not easily detectable with the transgenic mouse assay which is restricted to the detection of small deletion and insertions in the DNA. However, the negative Muta™mouse assay on mitomycin C has some limitations in the validity of the test system. With increased dose levels (MTD reached) and/or repeated application also gene mutagenic effects might be detected in the transgenic mouse assay.
Interestingly, substances with carcinogenic effects induced by nongenotoxic mechanisms gave mainly correct negative results in both test systems although the protocols for the transgenic mouse assays were not optimised except for chloroform.
Predictability of the transgenic animal assays and the mouse bone marrow micronucleus test for carcinogenicity
The sensitivity, specificity and predictive values to cancer for the Muta™mouse assay and the Big Blue® mouse assay combined, and the mouse bone marrow micronucleus test are documented in [Table 1]. In the present study data on 38 substances were available concerning carcinogenicity in mice and mutagenic effects in transgenic mice as well as mutagenic effects in the mouse bone marrow micronucleus test (). The two substances with inconclusive results in the mouse bone marrow micronucleus assay (phenobarbital & acrylamide) were not included in the final calculation data and in the comparison of the micronucleus test versus the transgenic mouse assay.
Although the data pool in this document is not sufficient for a comprehensive comparison (low number of examples, especially for specificity and negative predictability; limitations of most transgenic mouse assays with negative results) some differences were apparent between the two test systems.
The overall accuracy of the micronucleus test is lower than that of the transgenic mouse assays. This is mainly due to 11 negative results in the micronucleus test system (negative in the micronucleus test but positive in carcinogenicity studies) influencing the terms sensitivity and negative predictability. Three of these negative results in the micronucleus test are obtained with carcinogenic substances [chloroform, di-(2-ethylhexyl)phthalate, and tetrachloromethane] for which carcinogenic effects are considered to be of a nongenotoxic mechanism. However, chloroform, di-(2-ethylhexyl)phthalate and tetrachloromethane gave negative results in transgenic mice, so the comparison of both test system is not essentially affected and the evaluation „nongenotoxic” supported. For the other 8 substances out of these 11 with false negative results in the micronucleus test these results are explainable (see above): Ortho-anisidine (mutagenic/carcinogenic effects are restricted to the bladder), IQ (bone marrow presumably not target organ of genotoxicity in mice and more gene mutagenic than clastogenic), asbestos (local genotoxic/carcinogenic effects in the lung), 2,4-diaminotoluene (target organ liver, presumably not bone marrow), N-nitrosodiethylamine (target organ liver, more gene mutagenic than clastogenic), N-nitroso-N-propylamine (presumably more gene mutagenic than clastogenic), beta-propiolactone (mainly local effects and less systemic effects [in bone marrow]), tris(2,3-dibromopropyl)phosphate (systemic effects not related to the bone marrow).
The term negative predictability is also low in the transgenic mouse assay due to false negative results on six carcinogenic substances; for three of them, hydrazine, mitomycin C, and tetrachloroethylene (detailed treatise in section „direct comparison”, see above) genotoxic mechanisms are presumed. For hydrazine (no repeated application) and tetrachloroethylene (MTD not reached) limitations on the experimentel design might be the reason for the negative results. Mitomycin C is clearly more clastogenic than gene mutagenic, and the transgenic mouse with lacI and lacZ is possibly an unsuitable test system. For 3 out of the 6 substances the carcinogenic effects in mice were attributed to nongenotoxic mechanisms: chloroform, di-(2-ethylhexyl)phthalate and tetrachloromethane (see also above), all gave negative results in transgenic mice.
Only two substances with negative results in long-term carcinogenicity studies are available in the data pool: bromomethane and 2,6-diaminotoluene. Both gave correct negative results in the transgenic mouse assay (although of limited validity) but false positive results in the micronucleus test (see term specificity).
Generally, the differences between the two test systems might be due to the fact that 1) unequal genotoxic endpoints are investigated (chromosome aberration in the micronucleus test versus gene mutation in the transgenic mouse assay), 2) organotrophy of genotoxic effects (especially bone marrow not target organ) might play an essential role and 3) transgenic rodent assay conditions in the different systems may not be optimal for mutation detection.
Advantages and disadvantages of both test systems
A comparison of the transgenic mouse assays with the mouse bone marrow micronucleus test is limited by the fact that different genotoxic endpoints are studied in these two systems. In transgenic mouse assays, point mutations and small insertions and deletions are detected whereas in the mouse bone marrow assay, chromosome breakage leading to light microscopically visible micronuclei resulting from chromosome fragment or micronuclei originated from whole chromosomes are investigated.
Sensitivity of the test system
In comparison to other test systems in genotoxicity testing using endogenous target structures the spontaneous mutant frequency in the transgenic mouse assay is relatively high. This might be related to the fact that bacterial DNA is the target gene (high methylation rate) or the transgene is silent and no transcription related repair occurs like in endogenous genes which are more efficiently repaired [9]. In the mouse bone marrow micronucleus test the spontaneous rate of micronuclei is low ranging between 1-3 PCEs with micronuclei per 1000 PCEs. However, frequency of chromosome aberrations is not directly comparable with a gene mutantion frequency.
Comparing the target organs and cells at risk at the time of exposure, the mouse micronucleus test is restricted to one target organ, the bone marrow, especially to the erythroblasts. This limitation is not given in transgenic mouse assays: target cells are cells in all organs [195].
Considerations of animal welfare
Both test systems are similar in the number of animals used for a valid test. The minimal number of mice needed in the mouse bone marrow assay is 25 per gender (3 dose levels, vehicle control, positive control; 5 mice per group) using a treatment schedule with 2 or more applications at 24 h intervals and sampling 18-24 h following the final treatment. In the limit test (for a test substance of low toxicity) only one dose level of 2000 mg/kg bw is necessary (OECD guideline 474, [6]).
In transgenic mutation assays ca. 20 animals (3 dose groups and 1 concurrent vehicle control group in laboratories which already established this test system) are recommended per species and gender [196,197]. In terms of animal welfare, it is also desired to merge more than one in vivo genotoxicity assay such as transgenic mouse assay and micronucleus assay using the same animals for both assays.
Cost effectiveness
Due to the simplicity of the mouse bone marrow micronucleus assay and the use of systems for automated analysis, this test is less expensive than the transgenic mouse assay.
A comparison both test systems is presented in [Table 2].
Conclusions
In a comparison of the tests available to genetic toxicologists, the results from studies on substances which had been tested in transgenic mutagenicity assays Big Blue® mouse and the Muta™mouse were compared with those from the more traditional mouse bone marrow micronucleus test. The transgenic animal mutation assay, which is not yet used in toxicological screening, is not directly comparable with the micronucleus test, because different genetic endpoints are examined: chromosome aberration versus gene mutation. However, from the 39 substances, the majority gave the same positive or negative result in both test systems. The substances where differences occurred were discussed in more detail. The advantages and disadvantages of the transgenic Big Blue® mouse and the Muta™Mouse transgenic model compared to the micronucleus test were discussed and both systems were found to have a place in mutagenicity testing and to supplement each other. The transgenic animal assay has, however, some distinct advantages over the micronucleus test in that it is not restricted to one target organ and detects systemic as well as local mutagenic effects.
Authors’ contributions
UW was the main author. The other authors were involved in the discussions, writing small parts of text and in final preparation of the manuscript.
Acknowledgements
This paper is based on work performed by the authors in preparation of an Environmental Health Criteria document on Transgenic Animals in Mutagenicity Testing for the International Programme on Chemical Safety (IPCS). However, opinions expressed in this paper are the sole responsibility of the authors. We acknowledge the financial support of the German Federal Ministry for the Environment, Nature Conservation and Nuclear Safety.
References
| 1. | Heddle JA, Hite M, Kirkhart B, Mavournin K, MacGregor JT, Newell GW, Salamone MF: The induction of micronuclei as a measure of genotoxicity : A report of the U.S. Environmental Protection Agency gene-tox program. Mutat Res 1983, 123: 61-118.  |
| 2. | Mavournin KH, Blakey DH, Cimino MC, Salamone MF, Heddle JA: The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency gene-tox programm. Mutat Res 1990, 239: 29-80. |
| 3. | Shelby MD, Erexson GL, Hook GJ, Tice RR: Evaluation of a three-exposure mouse bone marrow micronucleus protocol: results with 49 chemicals. Environ Mol Mutagen 1993, 21: 160-179. |
| 4. | Morita T, Asano N, Awogi T, Sasaki Y, Sato S, Shimada H, Sutou S, Suzuki T, Wakata A, Sofuni T, Hayashi M: Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) The summary report of the 6th collaborative study by CSGMT/JEMS MMS. (Collaborative study of the micronucleus group test mammalian mutagenicity study group). Mutat Res 1997, 389: 3-122. |
| 5. | Morita T, Asano N, Awogi T, Sasaki Y, Sato S, Shimada H, Sutou S, Suzuki T, Wakata A, Sofuni T, Hayashi M: Erratum to “Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B). The summary report of the 6th collaborative study by CSGMT/JEMS NMS”. Mutat Res 1997, 391: 259-267. |
| 6. | OECD: OECD 474; mammalian erythrocyte micronucleus test; OECD guideline for the testing of chemicals . 1997. |
| 7. | Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Putman DL, Sorge JA, Short JM: Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ Mol Mutagen 1991, 18: 316-321. |
| 8. | Gossen JA, De Leeuw WJF, Tan CHT, Zwarthoff EC, Berends F, Lohman PHM, Knook DL, Vijg J: Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci U S A 1989, 86: 7971-7975. |
| 9. | RIVM: Mutagenicity of chemicals in genetically modified animals. RIVM Report no. 650210 002, TNO Report no. V99.1097 . Bilthoven: National Institute of Public Health and the Environmenta (RIVM); 2000. |
| 10. | Gossen J, Vijg J: Transgenic mice as model systems for studying gene mutations in vivo. Trends Genet 1993, 9: 27-31. |
| 11. | Shephard SE, Sengstag C, Lutz WK, Schlatter C: Mutations in liver DNA of lacI transgenic mice (Big Blue) following subchronic exposure to 2-acetylaminofluorene. Mutat Res 1993, 302: 91-96. |
| 12. | Hazardous Substances Data Bank (HSDB) 2-Acetylaminofluorene, CAS: 53-96-3 |
| 13. | National toxicology programm (NTP) 2-Acetylaminofluorene, Factsheet CAS: 53-96-3 |
| 14. | Brooks TM, Szegedi M, Rosher P, Dean SW: The detection of gene mutation in transgenic mice (Muta Mouse) following a single oral dose of 2-acetylaminofluorene. Mutagenesis 1995, 10: 149-150. |
| 15. | Ross JA, Leavitt SA: Induction of mutations by 2-acetylaminofluorene in lacI transgenic B6C3F1 mouse liver. Mutagenesis 1998, 13: 173-179. |
| 16. | Gunz D, Shephard SE, Lutz WK: Can nongenotoxic carcinogens be detected with the lacI transgenic mouse mutation assay? Environ Mol Mutagen 1993, 21: 209-211. |
| 17. | Genetic Toxicology (GENETOX) 4-Acetylaminofluorene, CAS: 28322-02-3 |
| 18. | Tinwell H, Lefevre PA, Ashby J: Relative activities of methyl methanesulphonate (MMS) as a genotoxin, clastogen and gene mutagen to the liver and bone marrow of Muta Mouse mice. Environ Mol Mutagen 1998, 32: 163-172. |
| 19. | IARC: Acrylamide. In Some industrial chemicals. Monographs on the evaluation of carcinogenic risks to humans, No. 60 . Lyon: International Agency for Research on Cancer (IARC); 1994:389-433. |
| 20. | Chemical Carcinogenesis Research Info System (CCRIS) 1996, Acrylamide, CAS: 79-06-1 |
| 21. | Myhr B: Validation studies with Muta mouse: a transgenic mouse model for detecting mutations in vivo. Environ Mol Mutagen 1991, 18: 308-315. |
| 22. | Hoorn AJW, Custer LL, Myhr BC, Brusick D, Gossen J, Vijg J: Detection of chemical mutagens using Muta Mouse: a transgenic mouse model. Mutagenesis 1993, 8: 7-10. |
| 23. | Krebs O, Favor J: Somatic and germ cell mutagenesis in lambda lacZ transgenic mice treated with acrylamide or ethylnitrosourea. Mutat Res 1997, 388: 239-248. |
| 24. | IARC: Aflatoxins. In Some naturally occuring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. Monographs on the evaluation of carcinogenic risks to humans, No. 56 . Lyon: International Agency for Research on Cancer (IARC); 1993:245-395. |
| 25. | Autrup H, Jorgensen ECB, Jensen O: Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: effect of phorone. Mutagenesis 1996, 11: 69-73. |
| 26. | Davies R, Oreffo VIC, Martin EA, Festing MFW, White INH, Smith LL, Styles JA: Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res 1997, 57: 1288-1293. |
| 27. | Dycaico MJ, Stuart GR, Tobal GM, de Boer JG, Glickman BW, Provost GS: Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis 1996, 17: 2347-2356. |
| 28. | Trzos RJ, Petzold GL, Brunden MN, Swenberg JA: The evaluation of sixteen carcinogens in the rat using the micronucleus test. Mutat Res 1978, 58: 79-86. |
| 29. | IARC: 4-Aminobiphenyl. In Some inorganic substances, chlorinated hydrocarbons, aromatic amines, N-nitroso compounds, and natural products. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 1 . Lyon: International Agency for Research on Cancer (IARC); 1971:74-79. |
| 30. | Genetic Toxicology (GENETOX) 4-Amino-1,1′-biphenyl, CAS: 92-67-1 |
| 31. | Chemical Carcinogenesis Research Info System (CCRIS) 4-Aminobiphenyl, CAS: 92-67-1 |
| 32. | Fletcher K, Tinwell H, Ashby J: Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of Muta Mouse transgenic mice. Mutat Res 1998, 400: 245-250. |
| 33. | IARC: IQ (2-Amino-3-methylimidazo[4,5-f]quinoline). In Some naturally occuring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. Monographs on the evaluation on carcinogenic risks to humans, No. 56 . Lyon: International Agency for Research on Cancer (IARC); 1993:165-195. |
| 34. | Davis CD, Dacquel EJ, Schut HAJ, Thorgeirsson SS, Snyderwine EG: In vivo mutagenicity and DNA adduct levels of heterocyclic amines in Muta Mice and c-myc/lacZ double transgenic mice. Mutat Res 1996, 356: 287-296. |
| 35. | Wild D, Gocke E, Harnasch D, Kaiser G, King MT: Differential mutagenic activity of IQ (2-amino-3-methylimidazo(4,5-F)quinoline) in Salomonella typhimurium strains in vitro and in vivo, in Drosophila, and in mice. Mutat Res 1985, 156: 93-102. |
| 36. | European Chemicals Bureau: European Union Risk Assessment Report, o-anisidine . Luxembourg: Office for Official Publications of the European Communities; 2002. |
| 37. | Ashby J, Short JM, Jones NJ, Lefevre PA, Provost GS, Rogers BJ, Martin EA, Parry JM, Burnette K, Glickman BW, Tinwell H: Mutagenicity of o-anisidine to the bladder of lacI-transgenic B6C3F1 mice: absence of 14C or 32P bladder DNA adduction. Carcinogenesis 1994, 15: 2291-2296. |
| 38. | IARC: Asbestos (Group 1). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volume 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 . Lyon: International Agency for Research on Cancer (IARC); 1987:106-116. |
| 39. | IARC: Asbestos. In Genetic and related effects: an updating of selected IARC monographs from volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 6 . Lyon: International Agency for Research on Cancer (IARC); 1987:77-80. |
| 40. | IARC: Asbestos. In Asbestos. Monographs on the evaluation of carcinogenic risk of chemicals to man, No. 14 . Lyon: International Agency for Research on Cancer (IARC); 1977:1-106. |
| 41. | Rihn B, Coulais C, Kauffer E, Bottin M-C, Martin P, Yvon F, Vigneron JC, Binet S, Monhoven N, Steiblen G, Keith G: Inhaled crocidolite mutagenicity in lung DNA. Environ Health Perspect 2000, 108: 341-346. |
| 42. | IARC: Benzene. In Some industrial chemicals and dyestuffs. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 29 . Lyon: International Agency for Research on Cancer (IARC); 1982:94-148. |
| 43. | WHO: Benzene. International Programme on Chemical Safety, Environmental Health Criteria 150 . Geneva: World Health Organization; 1993. |
| 44. | Provost GS, Mirsalis JC, Rogers BJ, Short JM: Mutagenic response to benzene and tris(2,3-dibromopropyl)-phosphate in the lambda lacI transgenic mouse mutation assay: a standardized approach to in vivo mutation analysis. Environ Mol Mutagen 1996, 28: 342-347. |
| 45. | Mullin AH, Nataraj D, Ren J-J, Mullin DA: Inhaled benzene increases the frequency and length of lacI deletion mutations in lung tissues of mice. Carcinogenesis 1998, 19: 1723-1733. |
| 46. | Mullin AH, Rando R, Esmundo F, Mullin DA: Inhalation of benzene leads to an increase in the mutant frequencies of a lacI transgene in lung and spleen tissues of mice. Mutat Res 1995, 327: 121-129. |
| 47. | Shelby M, Witt K: Comparison of results from mouse bone marrow chromosome aberration and micronucleus tests. Environ Mol Mutagen 1995, 25: 302-313. |
| 48. | Shimada H, Suzuki H, Itoh S, Hattori C, Matsuura Y, Tada S, Watanabe C: The micronucleus test of benzo(a)pyrene with mouse and rat peripheral blood reticulocytes. Mutat Res 1992, 278: 165-168. |
| 49. | WHO: Selected Non-heterocyclic Polycyclic Aromatic Hydrocarbons. International Programme on Chemical Safety, Environmental Helth Criteria 202 . Geneva: World Health Organisation; 1998. |
| 50. | Chemical carcinogenesis research information system (CCRIS) Benzo(a)pyrene, CAS: 50-32-8 |
| 51. | Hakura A, Tsutsui Y, Sonoda J, Kai J, Imade T, Shimada M, Sugihara Y, Mikami T: Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse). Mutat Res 1998, 398: 123-130. |
| 52. | Kosinska W, von Pressentin MdM, Guttenplan JB: Mutagenesis induced by benzo[a]pyrene in lacZ mouse mammary and oral tissues: comparisons with mutagenesis in other organs and relationships to previous carcinogenicity assays. Carcinogenesis 1999, 20: 1103-1106. |
| 53. | Mientjes EJ, Steenwinkel MJST, van Delft JHM, Lohman PHM, Baan RA: Comparison of the X-gal- and P-gal-based systems for screening of mutant lacZ phages originating from the transgenic mouse strain 40.6. Mutat Res 1996, 360: 101-106. |
| 54. | Hakura A, Tsutsui Y, Sonoda J, Mikami T, Tsukidate K, Sagami F, Kerns WD: Multiple organ mutation in the lacZ transgenic mouse (Muta Mouse) 6 months after oral treatment (5 days) with benzo[a]pyrene. Mutat Res 1999, 426: 71-77. |
| 55. | Skopek TR, Kort KL, Marino DR, Mittal LV, Umbenhauer DR, Laws GM, Adams SP: Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ Mol Mutagen 1996, 28: 376-384. |
| 56. | Shane BS, de Boer J, Watson DE, Haseman JK, Glickman BW, Tidall KR: LacI mutation spectra following benzo[a]pyrene treatment of Big Blue mice. Carcinogenesis 2000, 21: 715-725. |
| 57. | Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge JA, Putman DL, Short JM: Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. Proc Natl Acad Sci USA 1991, 88: 7958-7962. |
| 58. | Integrated Risk Information System (IRIS) Bromomethane, CAS: 74-83-9 |
| 59. | Chemical Carcinogenesis Research Info System (CCRIS) Methyl Bromide, CAS: 74-83-9 |
| 60. | Pletsa V, Steenwinkel MJ, van Delft JH, Baan RA, Kyrtopoulos SA: Methyl bromide causes DNA methylation in rats and mice but fails to induce somatic mutations in lambda lacZ transgenic mice. Cancer Lett 1999, 135: 21-27. |
| 61. | Araki A, Kato F, Matsushima T, Ikawa N, Nozaki K: Micronuclei induction of methyl bromide in rats and mice by sub-chronic inhalation toxicity test. Environ Muta Res Commun 1995, 17: 47-56. |
| 62. | IARC: 1,3-butadiene. In Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (part one). Monographs on the evaluation of carcinogenic risks to humans, No. 71 . Lyon: International Agency for Research on Cancer (IARC); 1999:109-225. |
| 63. | Recio L, Bond JA, Pluta LJ, Sisk SC: Use of transgenic mice for assessing the mutagenicity of 1,3-butadiene in vivo. IARC (Int Agency Res Cancer) Sci Pub 1993, 127: 235-243. |
| 64. | Sisk SC, Pluta L, Bond JA, Recio L: Molecular analysis of lacI mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. Carcinogenesis 1994, 15: 471-477. |
| 65. | Recio L, Meyer KG, Pluta LJ, Moss OR, Saranko CJ: Assessment of 1,3-butadiene mutagenicity in the bone marrow of B6C3F1 lacI transgenic mice (Big Blue): a review of mutational spectrum and lacI mutant frequency after a 5-day 625 ppm 1,3-butadiene exposure. Environ Mol Mutagen 1996, 28: 424-429. |
| 66. | Cunningham MJ, Choy WN, Arce GT, Rickard LB, Vlachos DA, Kinney LA, Sarrif AM: In vivo sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. Mutagenesis 1986, 1: 449-452. |
| 67. | IARC: Chlorambucil. In Some antineoplastic and immunosuppressive agents. Monographs on the evaluation of the carcinogenic risk chemicals to humans, No. 26 . Lyon: International Agency for Research on Cancer (IARC); 1981:115-136. |
| 68. | IARC: Chlorambucil (Group 1). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 . Lyon: International Agency for Research on Cancer (IARC); 1987:144-145. |
| 69. | Genetic Toxicology (GENETOX) Chlorambucil, CAS: 305-03-3 |
| 70. | Chemical Carcinogenesis Research Info System (CCRIS) Chlorambucil, CAS: 305-03-3 |
| 71. | Hazardous Substances Data Bank (HSDB) Chlorambucil, CAS: 305-03-3 |
| 72. | DFG: Chloroform. In Occupational toxicants – critical data evaluation for MAK values and classification of carcinogens, Volume 14. Deutsche Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 2000:19-58. |
| 73. | Robbiano L, Mereto E, Morando AM, Pastore P, Brambilla G: Increased frequency of micronucleated kidney cells in rats exposed to halogenated anaesthetics. Mutat Res 1998, 413: 1-6. |
| 74. | Butterworth BE, Templin MV, Constan AA, Sprankle CS, Wong BA, Pluta LJ, Everitt JI, Recio L: Long-term mutagenicity studies with chloroform and dimethylnitrosamine in female lacI transgenic B6C3F1 mice. Environ Mol Mutagen 1998, 31: 248-256. |
| 75. | IARC: Cyclophosphamide. In Some antineoplastic and immunosuppressive agents. Monographs on the evaluation of the carcinogenic risk chemicals to humans, No. 26 . Lyon: International Agency for Research on Cancer (IARC); 1981:165-202. |
| 76. | IARC: Cyclophosphamide (Group 1). In Overall evaluations of carcinogenicity: An updating of IARC MOnographs volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 . Lyon: International Agency for Research on Cancer (IARC); 1987:182-184. |
| 77. | Gorelick NJ, Andrews JL, de Boer JG, Young R, Gibson DP, Walker VE: Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice. Environ Mol Mutagen 1999, 34: 154-166. |
| 78. | Hoyes KP, Wadeson PJ, Sharma HL, Hendry JH, Morris ID: Mutation studies in lacI transgenic mice after exposure to radiation or cyclophosphamide. Mutagenesis 1998, 13: 607-612. |
| 79. | Walker VE, Andrews JL, Upton PB, Skopek TR, deBoer JG, Walker DM, Shi X, Sussman HE, Gorelick NJ: Detection of cyclophosphamide-induced mutations at the Hprt but not the lacI locus in splenic lymphocytes of exposed mice. Environ Mol Mutagen 1999, 34: 167-181. |
| 80. | Machemer L, Lorke D: Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems. Arch Toxicol 1978, 39: 187-197. |
| 81. | DFG: Toluene-2, 4-diamine. In Occupational toxicants – critical data evaluation for MAK values and classification of carcinogens, Volume 6. Deutsche Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 1994:339-352. |
| 82. | Cunningham ML, Hayward JJ, Shane BS, Tindall KR: Distinction of mutagenic carcinogens from a mutagenic noncarcinogen in the Big Blue transgenic mouse. Environ Health Perspect 1996, 104: 683-686. |
| 83. | Suter W, Ahiabor R, Blanco B, Locher F, Mantovani F, Robinson M, Sreenan G, Staedtler F, Swingler T, Vignutelli A, Perentes E: Evaluation of the in vivo genotoxic potential of three carcinogenic aromatic amines using the Big Blue transgenic mouse mutation assay. Environ Mol Mutagen 1996, 28: 354-362. |
| 84. | Hayward JJ, Shane BS, Tindall KR, Cunningham ML: Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene. Carcinogenesis 1995, 16: 2429-2433. |
| 85. | National Toxicology Program (NTP) 2,6-Toluenediamine dihydrochloride (2,6-diaminotoluene dihydrochloride), Factsheet TR-200, CAS 15481-70-6 |
| 86. | DFG: Di(2-ethylhexyl)phthalat (DEHP). In Gesundheitsschδdliche Arbeitsstoffe: Toxikologisch-arbeitsmedizinische Begründung von MAK-Werten, Volume 4. Deutsche Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 2002:1-81. |
| 87. | Chemical Carcinogenesis Research Info System (CCRIS) 7,12-Dimethylbenz(a)anthracene, CAS: 57-97-6 |
| 88. | Genetic Toxicology (GENETOX) 7,12-Dimethylbenz(a)anthracene, CAS: 57-97-6 |
| 89. | Hachiya N, Yajima N, Hatakeyama S, Yuno K, Okada N, Umeda Y, Wakata A, Motohashi Y: Induction of lacZ mutation by 7,12-dimethylbenz[a]anthracene in various tissues of transgenic mice. Mutat Res 1999, 444: 283-295. |
| 90. | Suzuki T, Itoh S, Nakajima M, Hachiya N, Hara T: Target organ and time-course in the mutagenicity of five carcinogens in Muta Mouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by the JEMS/MMS. Mutat Res 1999, 444: 259-268. |
| 91. | Ashby J, Brusick D, Myhr BC, Jones NJ, Parry JM, Nesnow S, Paton D, Tinwell H, Rosenkranz HS, Curti S, Gilman D, Callander RD: Correlation of carcinogenic potency with mouse-skin 32P-postlabeling and Muta Mouse lacZ-mutation data for DMBA and its K-region sulphur isostere: comparison with activities observed in standard genotoxicity assays. Mutat Res 1993, 292: 25-40. |
| 92. | Gorelick NJ, Andrews JL, Gu M, Glickman BW: Mutational spectra in the lacI gene in skin from 7,12-dimethylbenz[a]anthracene-treated and untreated transgenic mice. Mol Carcinog 1995, 14: 53-62. |
| 93. | Lonardo EC, Perdue PA, Freeman JJ: The detection of gene mutation in transgenic mice (Big Blue TM) following administration of a known mutagen 7,12-dimethylbenz[a]-anthracene – (DMBA). Abstr Annu Meet Environ Mut Soc 1996, 27 (Suppl 27) : 42. |
| 94. | Shelton SD, Cherry V, Manjanatha MG: Mutant frequency and molecular analysis of in vivo lacI mutations in the bone marrow of Big Blue rats treated with 7,12-dimethylbenz[a]anthracene. Environ Mol Mutagen 2000, 36: 235-242. |
| 95. | Manjanatha MG, Shelton SD, Aidoo A, Lyn-Cook LE, Casciano DA: Comparison of in vivo mutagenesis in the endogenous Hprt gene and the lacI transgene of Big Blue rats treated with 7,12-dimethylbenz[a]anthracene. Mutat Res 1998, 401: 165-178. |
| 96. | IARC: Ethylene Oxide. In Some industrial chemicals. Monographs on the evaluation of carcinogenic risks to humans, No. 60 . Lyon: International Agency for Research on Cancer (IARC); 1994:73-160. |
| 97. | Sisk SC, Pluta LJ, Meyer KG, Wong BC, Recio L: Assessment of the in vivo mutagenicity of ethylene oxide in the tissues of B6C3F1 lacI transgenic mice following inhalation exposure. Mutat Res 1997, 391: 153-164. |
| 98. | Walker VE, Sisk SC, Upton PB, Wong BA, Recio L: In vivo mutagenicity of ethylene oxide at the hprt locus in T-lymphocytes of B6C3F1 lacI transgenic mice following inhalation exposure. Mutat Res 1997, 392: 211-222. |
| 99. | Jenssen D, Ramel C: The micronucleus test as part of a short-term mutagenicity test program for the prediction of carcinogenicity evaluated by 143 agents tested. Mutat Res 1980, 75: 191-202. |
| 100. | IARC: Ethyl methanesulfonate. In Some anti-thyroid and related substances, nitrofurans and industrial chemicals. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 7 . Lyon: International Agency for Research on Cancer (IARC); 1974:245-251. |
| 101. | Dutch expert committee for occupational standards (DECOS): Health-based recommended occupational exposure limits for ethyl methanesulphonate (EMS) and methyl methanesulphonate (MMS) . Voorburg: Directorate-General of Labour, RA 4/89; 1989. |
| 102. | Chemical Carcinogenesis Research Info System (CCRIS) Ethyl methanesulphonate, CAS: 62-50-0 |
| 103. | Genetic Toxicology (GENETOX) Ethyl methanesulphonate, CAS: 62-50-0 |
| 104. | Suzuki T, Hayashi M, Sofuni T: Initial experiences and future directions for transgenic mouse mutation assays. Mutat Res 1994, 307: 489-494. |
| 105. | Suzuki T, Hayashi M, Wang X, Yamamoto K, Ono T, Myhr BC, Sofuni T: A comparison of the genotoxicity of ethylnitrosourea and ethyl methanesulfonate in lacZ transgenic mice (Muta Mouse). Mutat Res 1997, 395: 75-82. |
| 106. | Mientjes EJ, Luiten-Schuite A, van der Wolf E, Borsboom Y, Bergmanns A, Berends F, Lohman PHM, Baan RA, van Delft JHM: DNA adducts, mutant frequencies, and mutation spectra in various organs of lacZ mice exposed to ethylating agents. Environ Mol Mutagen 1998, 31: 18-31. |
| 107. | IARC: N-Nitroso-N-ethylurea. In Some N-nitro compounds. Monographs on the evaluation of carcinogenic risk of chemicals to humans, No. 17 . Lyon: International Agency for Research on Cancer (IARC); 1978:191-215. |
| 108. | Genetic Toxicology (GENETOX) 1-Ethyl-1-nitrosourea, CAS: 759-73-9 |
| 109. | JEMS/MMS: Organ variation in the mutagenicity of ethylnitrosourea in Muta Mouse: results of the collaborative study on the transgenic mutation assay by JEMS/MMS. Environ Mol Mutagen 1996, 28: 363-375. |
| 110. | Douglas GR, Jiao J, Gingerich JD, Gossen JA, Soper LM: Temporal and molecular characteristics of mutations induced by ethylnitrosourea in germ cells isolated from seminiferous tubules and in spermatozoa of lacZ transgenic mice. Proc Natl Acad Sci USA 1995, 92: 7485-7489. |
| 111. | Gorelick NJ, Andrews JL, Gibson DP, Carr GJ, Aardema MJ: Evaluation of lacI mutation in germ cells and micronuclei in peripheral blood after treatment of male lacI transgenic mice with ethylnitrosourea, isopropylmethane sulfonate or methylmethane sulfonate. Mutat Res 1997, 388: 187-195. |
| 112. | Putman D, Penn Ritter A, Carr GJ, Young RR: Evaluation of spontaneous and chemical-induced lacI mutations in germ cells from lambda/lacI transgenic mice. Mutat Res 1997, 388: 137-143. |
| 113. | Winegar RA, Carr G, Mirasalis JC: Analysis of the mutagenic potential of ENU and MMS in germ cells of male C57BL/6 lacI transgenic mice. Mutat Res 1997, 388: 175-178. |
| 114. | Katoh M, Horiya N, Valdivia RPA: Mutations induced in male germ cells after treatment of transgenic mice with ethylnitrosourea. Mutat Res 1997, 388: 229-237. |
| 115. | Zimmer DM, Harbach PR, Mattes WB, Aaron CS: Comparison of mutant frequencies at the transgenic lambda LacI and cII/cI loci in control and ENU-treated Big Blue mice. Environ Mol Mutagen 1999, 33: 249-256. |
| 116. | Provost GS, Short JM: Characterization of mutations induced by ethylnitrosourea in seminiferous tubule germ cells of transgenic B6C3F1 mice. Proc Natl Acad Sci USA 1994, 91: 6564-6568. |
| 117. | Skopek TR, Kort KL, Marino DR: Relative sensitivity of the endogenous hprt gene and lacI transgene in ENU-treated Big Blue B6C3F1 mice. Environ Mol Mutagen 1995, 26: 9-15. |
| 118. | Shibuya T, Morimoto K: A review of the genotoxicity of 1-ethyl-1-nitrosourea. Mutat Res 1993, 297: 3-38. |
| 119. | BUA: Hydrazin, Hydrazinhydrat und Hydrazinsulfate. Beratergremium für umweltrelevante Altstoffe, BUA Stoffbericht 205 . Stuttgart: S. Hirzel Wissenschaftliche Verlagsgesellschaft; 1996. |
| 120. | Douglas GR, Gingerich JD, Soper LM: Evidence for in vivo non-mutagenicity of the carcinogen hydrazine sulfate in target tissues of lacZ transgenic mice. Carcinogenesis 1995, 16: 801-804. |
| 121. | IARC: Methyl methanesulfonate. In Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Monographs on the evaluation of carcinogenic risks to humans, No. 71/3 . Lyon: International Agency for Research on Cancer (IARC); 1999:1059-1078. |
| 122. | IARC: Methyl methanesulphonate. In Some anti-thyroid and related substances, nitrofurans and industrial chemicals. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 7 . Lyon, International Agency for Research on Cancer (IARC); 1974:253-260. |
| 123. | Brooks TM, Dean SW: The detection of gene mutation in the tubular sperm of Muta™Mice following a single intraperitoneal treatment with methyl methanesulphonate or ethylnitrosourea. Mutat Res 1997, 388: 219-222. |
| 124. | Renault D, Brault D, Thybaud V: Effect of ethylnitrosourea and methyl methanesulfonate on mutation frequency in Muta™Mouse germ cells (seminiferous tubule cells and epididymis spermatozoa). Mutat Res 1997, 388: 145-153. |
| 125. | Itoh S, Miura M, Shimada H: Germ cell mutagenesis in lacZ transgenic mice treated with methyl methanesulfonate. Mutat Res 1997, 388: 223-228. |
| 126. | Mirsalis JC, Provost GS, Matthews CD, Hamner RT, Schindler JE, O’Loughlin KG, MacGregor JT, Short JM: Induction of hepatic mutations in lacI transgenic mice. Mutagenesis 1993, 8: 265-271. |
| 127. | Jensen D, Ramel C: Dose response at low doses of X-irradiation and MMS on the induction of micronuclei in mouse erythroblasts. Mutat Res 1976, 41: 311-319. |
| 128. | IARC: N-methyl-N’-nitro-N-nitrosoguanidine. In Some aromatic amines, hydrazine and related substances, N-nitroso compounds and miscellaneous alkylating agents. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 4 . Lyon: International Agency for Research on Cancer (IARC); 1974:183-196. |
| 129. | IARC: N-Methyl-N’-nitro-N-nitrosoguanidine. In Genetic and related effects: an updating of selected IARC monographs from volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 6 . Lyon: International Agency for Research on Cancer (IARC); 1987:394-398. |
| 130. | IARC: N-methyl-N’-nitro-N-nitrosoguandine (MNNG)) (Group 2A). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volume 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 . Lyon: International Agency for Research on Cancer (IARC); 1987:248-250. |
| 131. | Brault D, Bouilly C, Renault D, Thybaud V: Tissue-specific induction of mutations by acute oral administration of N-methyl-N’-nitro-N-nitrosoguanidine and -propiolactone to the Muta Mouse: preliminary data on stomach, liver and bone marrow. Mutat Res 1996, 360: 83-87. |
| 132. | Brooks TM, Dean SW: Detection of gene mutation in skin, stomach and liver of Muta Mouse following oral or topical treatment with N-methyl-N’-nitro-N-nitrosoguanidine or 1-chloromethylpyrene: some preliminary observations. Mutagenesis 1996, 11: 529-532. |
| 133. | IARC: N-nitroso-N-methylurea. In Some N-nitroso compounds. Monographs on the evaluation on carcinogenic risk of chemicals to humans, No. 17 . Lyon: International Agency for Research on Cancer (IARC); 1978:227-255. |
| 134. | Genetic Toxicology (GENETOX) 1-Methyl-1-nitrosourea, CAS: 684-93-5 |
| 135. | von Pressentin MdM, Kosinska W, Guttenplan JB: Mutagenesis induced by oral carcinogens in lacZ mouse (Muta Mouse) tongue and other oral tissues. Carcinogenesis 1999, 20: 2167-2170. |
| 136. | Monroe JJ, Kort KL, Miller JE, Marino DR, Skopek TR: A comparative study of in vivo mutation assays: analysis of hprt, lacI, cII/cI as mutational targets for N-nitroso-N-methylurea and benzo[a]pyrene in Big Blue mice. Mutat Res 1998, 421: 121-136. |
| 137. | Shephard SE, Gunz D, Schlatter C: Genotoxicity of agaritine in the lacI transgenic mouse mutation assay: evaluation of the health risk of mushroom consumption. Food Chem Toxicol 1995, 33: 257-264. |
| 138. | Provost GS, Kretz P, Hamner RT, Matthews CD, Rogers BJ, Lundberg KS, Dycaico MJ, Short JM: Transgenic systems for in vivo mutation analysis. Mutat Res 1993, 288: 133-149. |
| 139. | IARC: Mitomycin C. In Some naturally occuring substances. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 10 . Lyon: International Agency for Research on Cancer (IARC); 1976:171-179. |
| 140. | Chemical Carcinogenesis Research Info System (CCRIS) Mitomycin C, CAS: 50-07-7 |
| 141. | Genetic Toxicology (GENETOX) 1998, Mitomycin C, CAS: 50-07-7 |
| 142. | Suzuki T, Hayashi M, Sofuni T, Myhr BC: The concomitant detection of gene mutation and micronucleus induction by mitomycin C in vivo using lacZ transgenic mice. Mutat Res 1993, 285: 219-224. |
| 143. | Genetic Toxicology (GENETOX) 4-Nitroquinoline 1-Oxide, CAS: 56-57-5 |
| 144. | Chemical carcinogenesis research information system (CCRIS) 4-Nitroquinoline 1-Oxide, CAS: 56-57-5 |
| 145. | Nakajima M, Kikuchi M, Saeki K, Miyata Y, Terada M, Kishida F, Yamamoto R, Furihata C, Dean SW: Mutagenicity of 4-nitroquinoline 1-oxide in the Muta Mouse. Mutat Res 1999, 444: 321-336. |
| 146. | IARC: N-Nitrosodiethylamine. In Some N-nitro compounds. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 17 . Lyon: International Agency for Research on Cancer (IARC); 1978:89-106. |
| 147. | Chemical Carcinogenesis Research Info System (CCRIS) N, N-Diethylnitrosamine, CAS: 55-18-5 |
| 148. | Genetic Toxicology (GENETOX) Diethylnitrosamine, CAS: 55-18-5 |
| 149. | Okada N, Honda A, Kawabata M, Yajima N: Sodium phenobarbital-enhanced mutation frequency in the liver DNA of lacZ transgenic mice treated with diethylnitrosamine. Mutagenesis 1997, 12: 179-184. |
| 150. | Suzuki T, Hayashi M, Myhr B, Sofuni T: Diethylnitrosamine is mutagenic in liver but not in bone marrow of lacZ transgenic mice (Muta Mouse). Honyu Dobutsu Shiken Bunkakai Kaiho 1995, 3: 33-39. |
| 151. | IARC: N-nitrosodimethylamine. In Some N-nitroso compounds. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 17 . Lyon: International Agency for Research on Cancer (IARC); 1978:125-175. |
| 152. | Genetic Toxicology (GENETOX) Dimethylnitrosamine, CAS: 62-75-9 |
| 153. | Schmezer P, Eckert C, Liegibel U, Klein R, Bartsch H: Use of transgenic mutational test systems in risk assessment of carcinogens. Arch Toxicol 1998, (Suppl 20) : 321-330. |
| 154. | Suzuki T, Miyata Y, Saeki K, Kawazoe Y, Hayashi M, Sofuni T: In vivo mutagenesis by the hepatocarcinogen quinoline in the lacZ transgenic mouse: evidence for its in vivo genotoxicity. Mutat Res 1998, 412: 161-166. |
| 155. | Tinwell H, Lefevre PA, Ashby J: Response of the MutaMouse lacZ/galE-transgenic mutation assay to DMN: Comparison with the corresponding Big Blue (lacI) responses. Mutat Res 1994, 307: 169-173. |
| 156. | Shane BS, Smith-Dunn DL, de Boer JG, Glickman BW, Cunningham ML: Mutant frequencies and mutation spectra of dimethylnitrosamine (DMN) at the lacI and cII loci in the livers of Big Blue transgenic mice. Mutat Res 2000, 452: 197-210. |
| 157. | Suzuki T, Itoh T, Hayashi M, Nishikawa Y, Ikezaki S, Furukawa F, Takahashi M, Sofuni T: Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice. Environ Mol Mutagen 1996, 28: 348-353. |
| 158. | Wang X, Suzuki T, Itoh T, Honma M, Nishikawa A, Furukawa F, Takahashi M, Hayashi M, Kato T, Sofuni T: Specific mutational spectrum of dimethylnitrosamine in the lacI transgene of Big Blue C57BL/6 mice. Mutagenesis 1998, 13: 625-630. |
| 159. | Gollapudi BB, Jackson KM, Stott WT: Hepatic lacI and cII mutation in transgenic (<lambda]liz) b=”” dimethylnitrosamine.=”” with=”” treated=”” rats=””> Mutat Res 1998, 419: 131-135. </lambda]liz)> |
| 160. | DFG: N-Nitrosamines. In Occupational toxicants – critical data evaluation for MAK values and classification of carcinogens, Volume 1. Deutsche Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 1991:261-289. |
| 161. | Chemical Carcinogenesis Research Info System (CCRIS) N,N-Dipropylnitrosamine, CAS: 621-64-7 |
| 162. | Genetic Toxicology (GENETOX) N,N-Dipropylnitrosamine, CAS: 621-64-7 |
| 163. | Integrated Risk Information System (IRIS) N-Nitrosodi-N-propylamine, CAS: 621-64-7 |
| 164. | Itoh S, Miura M, Itoh T, Miyauchi Y, Suga M, Takahashi Y, Kasahara Y, Yamamura E, Hirono H, Shimada H: N-nitrosodi-n-propylamine induces organ specific mutagenesis with specific expression times in lacZ transgenic mice. Mutat Res 1999, 444: 309-319. |
| 165. | IARC: Phenobarbital and phenobarbital sodium. In Some miscellaneous pharmaceutical substances. Monographs on the evaluation of carcinogenic risk of chemicals to man, No. 13 . Lyon: International Agency for Research on Cancer (IARC); 1977:157-181. |
| 166. | IARC: Phenobarbital. In Genetic and related effects: an updating of selected IARC monographs from volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 6 . Lyon: International Agency for Research on Cancer (IARC); 1987:455-458. |
| 167. | IARC: Phenobarbital (Group 2b). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 . Lyon: International Agency for Research on Cancer (IARC); 1987:313-315. |
| 168. | Tombolan F, Renault D, Brault D, Guffroy M, Pιrin F, Thybaud V: Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of Muta Mice treated with 5,9-dimethyldibenzo[c,g]carbazole. Carcinogenesis 1999, 20: 1357-1362. |
| 169. | Shane BS, Smith-Dunn DL, deBoer JG, Glickman BW, Cunningham ML: Subchronic administration of phenobarbital alters the mutation spectrum of lacI in the livers of Big Blue transgenic mice. Mutat Res 2000, 448: 69-80. |
| 170. | IARC: Procarbazine hydrochloride. In The antineoplastic and immunosuppressive agents. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 26 . Lyon: International Agency for Research on Cancer (IARC); 1981:311-339. |
| 171. | IARC: Procarbazine hydrochloride (Group 2A). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl.7 . Lyon: International Agency for Research on Cancer (IARC); 1987:327-328. |
| 172. | Suzuki T, Uno Y, Idehara K, Baba T, Maniwa J, Ohkouchi A, Wang X, Hayashi M, Sofuni T, Tsuruoka M, Miyajima H, Kondo K: Procarbazine genotoxicity in the Muta Mouse; strong clastogenicity and organ-specific induction of lacZ mutations. Mutat Res 1999, 444: 269-281. |
| 173. | Pletsa V, Valavanis C, van Delft JHM, Steenwinkel M-JST, Kyrtopoulos SA: DNA damage and mutagenesis induced by procarbazine in lacZ transgenic mice: evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine. Carcinogenesis 1997, 18: 2191-2196. |
| 174. | Kliesch U, Danford N, Adler I-D: Micronucleus test and bone-marrow chromosome analysis : a comparison of 2 methods in vivo for evaluating chemically induced chromosomal alterations. Mutat Res 1981, 80: 321-332. |
| 175. | DFG: -Propiolacton. In Gesundheitsschδdliche Arbeitsstoffe: Toxikologisch-arbeitsmedizinische Begründung von MAK-Werten Volume 9, Deutsche Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 1976:1-8. |
| 176. | ACGIH: Beta-Propiolactone. In Documentation of the Threshold Limit Values (TLV) and Biological Exposure Indices (BEI) . Cincinnati (Ohio): American Conference of Governmental Industrial Hygienists (ACGIH); 1998:1292-1293. |
| 177. | Chemical Carcinogenesis Research Info System (CCRIS) Beta-Propiolactone, CAS: 57-57-8 |
| 178. | Genetic Toxicology (GENETOX) Beta-Propiolactone, CAS: 57-57-8 |
| 179. | Integrated Risk Information System (IRIS) Quinoline, CAS: 91-22-5 |
| 180. | Chemical Carcinogenesis Research Info System (CCRIS) Quinoline, CAS: 91-22-5 |
| 181. | Genetic Toxicology (GENETOX) Quinoline, CAS: 91-22-5 |
| 182. | Hazardous Substances Data Bank (HSDB) Quinoline, CAS: 91-22-5 |
| 183. | Miyata Y, Saeki K, Kawazoe Y, Hayashi M, Sofuni T, Suzuki T: Antimutagenic structural modification of quinoline assessed by an in vivo mutagenesis assay using lacZ-transgenic mice. Mutat Res 1998, 414: 165-169. |
| 184. | Hamoud MA, Ong T, Petersen M, Nath J: Effects of quinoline and 8-hydroxyquinoline on mouse bone marrow erythrocytes as measured by the micronucleus assay. Teratog Carcinog Mutagen 1989, 9: 111-118. |
| 185. | DFG: Carbon tetrachloride. In Occupational toxicants – critical data evaluation for MAK values and classification of carcinogens Volume 18, Deutsche Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 2002:82-106. |
| 186. | DFG: Trichloroethylene. In Occupational toxicants – critical data evaluation for MAK values and classification of carcinogens, Volume 10. Deutsch Forschungsgemeinschaft (DFG) . Weinheim: Wiley-VCH; 1998:221-236. |
| 187. | Douglas GR, Gingerich JD, Soper LM, Potvin M, Bjarnason S: Evidence for the lack of base-change abd small-deletion mutation induction by trichloroethylene in lacZ transgenic mice. Environ Mol Mutagen 1999, 34: 190-194. |
| 188. | WHO: Tris(2,3-dibromopropyl) phosphate and Bis(2,3-dibromopropyl) phosphate. International Programme on Chemical Safety, Environmental Health Criteria 173 . Geneva: World Health Organisation; 1995. |
| 189. | Chemical Carcinogenesis Research Info System (CCRIS) Tris(2,3-Dibromopropyl)phosphate, CAS: 126-72-7 |
| 190. | Genetic Toxicology (GENETOX) Tris(2,3-Dibromopropyl)phosphate, CAS:126-72-7 |
| 191. | de Boer JG, Mirsalis JC, Provost GS, Tindall KR, Glickman BW: Spectrum of mutations in kidney, stomach, and liver from lacI transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate. Environ Mol Mutagen 1996, 28: 418-423. |
| 192. | IARC: Urethane. In Some anti-thyroid and related substances, nitrofurans and industrial chemicals. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No.7 . Lyon: International Agency for Research on Cancer (IARC); 1974:111-140. |
| 193. | Genetic Toxicology (GENETOX) Urethane, CAS: 51-79-6 |
| 194. | Williams CV, Fletcher K, Tinwell H, Ashby J: Mutagenicity of ethyl carbamate to lacZ-transgenic mice. Mutagenesis 1998, 13: 133-137. |
| 195. | Nohmi T, Suzuki T, Masumura K-I: Recent advances in the protocols of transgenic mouse mutation assays. Mutat Res 2000, 455: 191-215. |
| 196. | Mirsalis J, Monforte J, Winegar R: Transgenic animal models for detection of in vivo mutations. Annu Rev Pharm Toxicol 1995, 35: 145-164. |
| 197. | Heddle JA, Dean S, Nohmi T, Boerrigter M, Casciano D, Douglas GR, Glickman BW, Gorelick NJ, Mirsalis JC, Martus H-J, Skopek TR, Thybaud V, Tindall KR, Yajima N: In vivo transgenic mutation assays. Environ Mol Mutagen 2000, 35: 253-259. |
Tables